The price of Novo Nordisk A/S (NVO) on October 9, 2026 is 38.58 USD, +1.03% on the day. Over 52 weeks the stock traded between 35.12 USD and 64.16 USD; the price now sits 11% of the way up that range. Over the past year the price changed by -35.31%.
Prices delayed by 15 minutes
Next earnings report: 04 November 2026 · Earnings calendar
Novo Nordisk A/S trades on NYSE under the ticker NVO. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks NVO has traded between 35.12 $ and 64.16 $. As of 09 October 2026 the price stood 10.54 % of the way from the 52-week low to the high.
Over one year NVO shares fell 35.31 %; over six months they rose 1.98 %. Volatility over 90 days is 38.42 %. Dividends are not included: this is price change only, as of 09 October 2026.
Novo Nordisk A/S reported revenue of 309.1B DKK and net income of 102.4B DKK for the latest fiscal year. Net margin is 33.14 %. Revenue changed by +6.43 % year over year. Earnings per share are 23.03 DKK.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 37.80 | 38.23 | 37.51 | 38.18 | 12M |
| 07 October 2026 | 37.57 | 38.47 | 37.51 | 38.26 | 14M |
| 06 October 2026 | 37.35 | 37.53 | 36.85 | 37.53 | 14M |
| 05 October 2026 | 36.94 | 37.61 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the fiscal year ended 31 December 2025
The sector median covers every company in the sector on the US market, loss-making ones included.
Novo Nordisk A/S (NVO) is a public company in the healthcare sector. Its common stock trade on NYSE.
Over the trailing twelve months as reported to 2025-12-31, revenue was 309.1bn, net income was 102.4bn.
This summary is compiled automatically from SEC filings and exchange data.
Address:NOVO ALLE DK 2880, BAGSVAERD DENMARK, 00000, DK
NVO has a return on equity of 52.79 %, above the sector median of −41.68 %. Return on assets is 18.87 %, above the sector median of −32.11 %. Operating margin is 41.30 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 36.86 |
| 37.54 |
| 19M |
| 02 October 2026 | 37.64 | 37.65 | 37.17 | 37.32 | 10M |
| 01 October 2026 | 37.80 | 37.97 | 37.37 | 37.40 | 13M |
| 30 September 2026 | 38.05 | 38.77 | 37.89 | 37.91 | 22M |
| 29 September 2026 | 38.21 | 38.38 | 38.05 | 38.31 | 9M |
| 28 September 2026 | 38.40 | 38.90 | 38.23 | 38.71 | 11M |
| 25 September 2026 | 38.81 | 38.83 | 38.41 | 38.80 | 10M |
| 24 September 2026 | 37.95 | 38.72 | 37.92 | 38.62 | 20M |
| 23 September 2026 | 38.90 | 39.14 | 38.16 | 38.17 | 18M |
| 22 September 2026 | 39.50 | 39.89 | 39.11 | 39.40 | 24M |
| 21 September 2026 | 41.05 | 41.17 | 39.54 | 39.80 | 49M |
| 18 September 2026 | 43.50 | 43.54 | 42.78 | 43.24 | 10M |
| 17 September 2026 | 41.98 | 43.44 | 41.96 | 43.19 | 13M |
| 16 September 2026 | 42.47 | 42.72 | 41.47 | 41.71 | 12M |
| 15 September 2026 | 42.73 | 43.00 | 42.40 | 42.53 | 9M |
| 14 September 2026 | 43.66 | 43.71 | 43.07 | 43.45 | 7M |
| 11 September 2026 | 43.20 | 43.50 | 42.72 | 43.07 | 11M |